2020 Volume 53 Issue 3 Pages 213-220
A 78-year-old man presented with stage IV gastric cancer with hepatic hilar and tracheobronchial lymph node metastases. He was treated with combined chemotherapy (paclitaxel+S-1). His cancer was subsequently found to express HER2; therefore, we changed the chemotherapy to a regimen containing trastuzumab (trastuzumab, cisplatin, and capecitabine). After 17 courses of chemotherapy, esophagogastroduodenoscopy only showed a scar, and the metastatic lymph nodes had reduced significantly in size. We performed distal gastrectomy with D2, #8p, and #13 lymph node dissection. The histopathological examination showed tumor cells remaining in the #4d lymph node, but the primary lesion exhibited a complete histopathological response. A trastuzumab-containing regimen was suggested to be useful as a preoperative chemotherapy for HER2-positive gastric cancer.
